Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.33 |
| ▸ | TRDMT1 | O14717 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1140561 | 0.87 | SLC28A1 (0.37) | NNMTADORA1SLC28A1ADORA3ADORA2A | |
| Phosphoric Acid SCHEMBL888221 | 0.87 | SLC28A1 (0.35) | NNMTSLC29A1ADORA1SLC28A1ADORA3 | |
| SCHEMBL888214 | 0.85 | NNMT (0.36) | NNMTSLC29A1ADORA1SLC28A1TRDMT1 | |
| SCHEMBL888231 | 0.82 | SLC28A1 (0.40) | SLC29A1ADORA1SLC28A1ADORA3ADORA2A | |
| SCHEMBL888100 | 0.81 | SLC28A1 (0.42) | SLC29A1ADORA1SLC28A1ADORA3ADORA2A | |
| Phosphoric Acid SCHEMBL888082 | 0.78 | SLC28A1 (0.40) | SLC29A1ADORA1SLC28A1ADORA3ADORA2A | |
| SCHEMBL1140223 | 0.78 | SLC28A1 (0.38) | NNMTADORA1SLC28A1ADORA3ADORA2A | |
| SCHEMBL887961 | 0.76 | ENPP1 (0.43) | NNMTSLC29A1TRDMT1 | |
| SCHEMBL12570176 | 0.74 | SLC29A1 (0.49) | SLC29A1ADORA1ADORA3 | |
| SCHEMBL12835761 | 0.74 | SLC29A1 (0.49) | SLC29A1ADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125856-B1 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN INC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-8969535-B2 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130072388-A1 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2013-03-21 | — | — | US | disclosed |
| US-8361727-B2 | 3′OH-unblocked, nucleotides and nucleosides base modified with labels and photocleavable, terminating groups and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110287427-A1 | 3'OH-UNBLOCKED, NUCLEOTIDES AND NUCLEOSIDES BASE MODIFIED WITH LABELS AND PHOTOCLEAVABLE, TERMINATING GROUPS AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-7964352-B2 | 3′-OH unblocked nucleotides and nucleosides, base modified with labels and photocleavable, terminating groups and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7897737-B2 | Polymorphic identification; fluorescent dyes | LASERGEN, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090081686-A1 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20080132692-A1 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | AGILENT TECHNOLOGIES, INC. | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132692-A1 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | UNG, DCLRE1B, NT5C3B | NNMT 209/4885SLC29A1 213/4885ADORA1 332/4885 |
| US-20130072388-A1 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN IN DNA SEQUENCING | UNG, NT5C3B, OGG1 | NNMT 182/4885SLC29A1 189/4885ADORA1 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.